European Heart Journal - Cardiovascular Pharmacotherapy
European Heart Journal - Cardiovascular Pharmacotherapy is a journal indexed in SJR in Cardiology and Cardiovascular Medicine and Pharmacology (medical) with an H index of 45. It has an SJR impact factor of 2,043 and it has a best quartile of Q1. It has an SJR impact factor of 2,043.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
2,043
H-index
45
Docs (year)
106
Docs 3y
343
Total refs
3032
Cites 3y
1284
Citable 3y
242
Cites/Doc 2y
4.38
Ref/Doc
28.6
Immediate OA
—
Embargoed OA
NPD
Non OA / Submission
—
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Atrial fibrillation and its complications: a focus on identifying risk factors and risk stratification
View moreWorldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration
View moreCongestive heart failure: More common as well as an important cardiovascular outcome - reply
View moreComparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries
View moreClinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
View moreChanging paradigms in oral anticoagulation during cardioversion in Europe
View moreCenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancingin vivoandex vivoactions
View moreCenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states
View moreCardiovascular safety of anti-diabetic drugs
View moreCardiovascular pharmacotherapy
View moreCardiovascular pharmacology: a look back and a glimpse into the future
View moreCardio-renal protection through renin-angiotensin-aldosterone system inhibition: current knowledge and new perspectives
View moreBack to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure
View more2017 ESC guidelines focus on dual antiplatelet therapy
View moreAntithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data
View moreAntithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with
View moreAntiplatelet treatment in acute coronary syndrome. Still an issue
View moreAnticoagulation in COVID-19
View moreAnnual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
View moreAnnual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System
View moreAngiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy
View moreAdjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review
View moreAdherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry
View moreA translational viewpoint explaining its potential salutary effects
View more